Clinical trial
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
NCT00394472 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00394472 |
|---|---|
| Title | Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients |
| Official title | A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease (GERD) |
| Intervention type | Drug |
| Interventions | AZD3355 |
| Enrollment | 244 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Nov 1, 2006 |
| Last update posted | Mar 18, 2013 |
| Countries | Australia, Belgium, France, Germany, Hungary, Netherlands, Norway, Romania |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: